Subscribe   RSS Contact Us

Holcombe’s E&C Testimony: PDUFA VI Will Take Patient-focused Drug Development to New Level

March 23, 2017 – In testimony before the House Energy and Commerce Committee’s Subcommittee on Health yesterday, Biotechnology Industry Organization ... read more

Gottlieb Is “Known” Entity to Pharma Industry

March 20, 2017 – Although medical marketers are very familiar with Scott Gottlieb, President Donald Trump’s choice for the top ... read more

Industry Groups Oppose Oregon Bill Calling for Advertising Price Disclosure

March 9, 2017 – Four major advertising and media industry groups have issued a joint letter opposing an Oregon bill ... read more

Trump Needs to Take a Closer Look at FDA Performance

March 8, 2017 – In an open letter to President Donald Trump, Pharmalot’s Ed Silverman asks that before Trump criticizes ... read more

Industry Peacekeeping with President Trump Holds Promise But Portends Danger

By John Kamp, Executive Director, Coalition for Healthcare Communication [Editor’s Note: This “The Final Word” column appeared in the February ... read more

Citizen Petition Calls on FDA to Stay Final Rule Establishing “Totality of the Evidence” Standard for Intended Use

Feb. 24, 2017 – The FDA recently published a final rule on intended use and adequate directions for use that ... read more

Previous Next

OPDP Cites Two Companies for YouTube Videos Featuring INDs

Jan. 3, 2017 – In its last blast of 2016, the FDA’s Office of Prescription Drug Promotion (OPDP) sent Untitled Letters to two companies on Dec. 21, both citing videos available on YouTube that allegedly promote investigational new drugs (INDs) as safe and effective for the purposes for which they are being investigated. These Untitled Letters bring the 2016 tally up to eight; with the three Warning Letters issued for promotional infractions, the total number of enforcement actions in 2016 was 11.

The Untitled Letter sent to Chiasma Inc. cites a video that promotes octreotide capsules (also referred to by the proprietary name, MYCAPSSA™), an IND for which there is no marketing authorization in the United States. Indeed, the FDA had previously told Chiasma that it did not believe the company’s application had provided substantial evidence or efficacy to warrant approval, and “advises Chiasma that it would need to conduct another clinical trial in order to overcome this deficiency.”

The video at issue “presents claims that promote ocreotide capsules as safe and effective for the purpose for which it is being investigated” – to treat acromegaly.

“These claims make numerous positive and conclusory statements about the safety and effectiveness of ocreotide capsules, such as suggesting that ‘the drug is safe’ and ‘the effectiveness of the drug was proven in clinical trials.’” Although OPDP acknowledges that the statement “Product is an investigational new drug and not available for commercial distribution” is included as a SUPER on the screen for eight seconds at the end of the video, it states that “there is no disclaimer that would sufficiently mitigate the extensive claims and presentations throughout the majority of this video.”

The Untitled Letter sent to Zydus Discovery DMCC cites a video that suggests saroglitazar tablets (also referred to by the proprietary name LIPAGLYN™), an IND, are safe and effective to treat patients with diabetic dyslipidemia and hypertriglyceridemia with Type 2 diabetes specifically, although “there is no marketing authorization within the United States” for the drug.

According to OPDP, the video includes claims and presentations that promote the IND for purposes for which it has not been approved by the FDA, even though the product is approved in another country. “The claims and presentations, including the broad statements regarding the drug’s approval as the ‘world’s first’ furthermore are misleading,” the OPDP letter states, and suggests “that the drug is approved throughout the world, including the United States, when that is not the case.”

In both cases, the OPDP requests that the companies cease violating the FD&C Act and submit written responses to the OPDP by Jan. 6, 2017.